IPHA Earnings

IPHA reported its earnings on 2025-11-13, showcasing a revenue of 2.32M against an estimate of 2.32M, resulting in a 0% surprise. The EPS was -0.14, surpassing the expected -0.14 by -1.57%. The stock experienced a -5.21% price change on the earnings day and a -6.25% change over the next five days, reflecting market reactions to the results.

Following IPHA's earnings announcement on 2025-11-13, the stock price moved by -5.21% on the day of the release. Over the subsequent five days, it saw a -6.25% change. Historically, IPHA's stock price tends to shift by an average of 3.18% in the 10 days leading up to earnings and -0.96% in the 10 days following, providing insight into potential market.

For , analysts estimate IPHA's annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between IPHA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IPHA's stock price typically moves by 3.18% in the 10 days before its earnings and -0.96% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call presents a mixed picture. While there are positive developments in clinical trials and partnerships, there are risks associated with trial outcomes and partnership dependencies. Financials show reduced R&D expenses, but operating expenses remain high, and cash position is stable. The Q&A reveals interest in IPH4502 and MATISSE programs, but management's lack of clarity on certain details introduces uncertainty. Overall, the sentiment is balanced by positive clinical progress and financial stability, offset by risks and unclear guidance, suggesting a neutral stock price reaction in the short term.